2月19日 - ** 制药商Madrigal Pharmaceuticals MDGL.O股价盘前下跌6%，报 462.10美元
** 公司报告第四季度每股亏损2.57美元，分析师预计每股亏损40美分 - LSEG数据
** MDGL 公布第四季度净营收 3.211 亿美元，预计为 3.125 亿美元。
** Truist Securities称，"第四季度和第三季度12%的收入增长反映了公司的持续进步，这将有助于增强投资者对公司继续执行Rezdiffra项目的信心"。
** 截至12月31日，Madrigal拥有现金、现金等价物、受限现金和有价证券9.886亿美元，而一年前为 9.313亿美元。
** 2025 年，MDGL 增长了 88.7%
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.